Shares of Immunovant (IMVT) after rallying after Roche’s (RHHBY) Chugai Pharmaceutical announced results from its Phase III LUMINESCE study of Enspryng, an investigational treatment for generalized myasthenia gravis. Statistically significant data was observed in its primary endpoint, however the results did not reach expectations on the degree of clinical benefit, the company in a statement. Shares of Immunovant are up 18%, or $5.53, to $37.10 in premarket trading. Argenx (ARGX) shares are also moving higher.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
